T.T. Macejko scite author profile

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

T.T. Macejko

Multicenter Clinical Evaluation of Bepotastine Besilate Ophthalmic Solutions 1.0% and 1.5% to Treat Allergic Conjunctivitis

Bepotastine Besilate Ophthalmic Solution 1.5% for Up to 8 Hours Following Dosing Reduces Total Non-Ocular Symptoms, Rhinorrhea, and Tearing in a Multi-Site Clinical Model of Allergic Conjunctivitis

Bepotastine Besilate Ophthalmic Solution 1.0% Provides Rapid Relief of Rhinorrhea, Total Non-Ocular Symptoms, Tearing, and Ciliary and Episcleral Hyperemia Following Dosing in a Multi-Site Clinical Model of Allergic Conjunctivitis

Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Nonocular Composite Symptom (NOCS) Scores 16 Hours Following Dosing in the Conjunctival Allergen Challenge (CAC) Model of Allergic Conjunctivitis

Efficacy and Safety Of a New Olopatadine Hydrochloride, 0.77% Ophthalmic Formulation In Patients With Allergic Conjunctivitis Using The Conjunctival Allergen Challenge (CAC) Model (NCT01479374)

Contact Info

Product

Resources

About